A new dawn for Oxford BioMedica…again
This article was originally published in Scrip
Executive Summary
For Oxford BioMedica 2013 was quite an annus horribilis. However, the UK biotechnology firm is still confident it will rise up from the ashes this year – with CEO John Dawson saying that despite reporting pre-tax losses of more than £12m last year, the company is "operationally now in its strongest position ever."
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.